Bt354
Bt354 is an orally active STAT3 inhibitor with IC50 values of 4.6 μM (DU145), 6.5 μM (MDA-MB-435) and 7.2 μM (MDA-MB-231), respectively. Bt354 induces cell cycle arrest and apoptosis, and downregulates epithelial-mesenchymal transition-related genes. Bt354 exhibits anti-angiogenic and anti-inflammatory activities, attenuates the polarization of M1 microglia and A1 astrocytes, suppresses inflammasome-related signaling pathways, and alleviates mechanical hyperalgesia and thermal hyperalgesia. Bt354 can be used in research related to glioblastoma multiforme, triple-negative breast cancer, prostate cancer and neuropathic pain.
For research use only. We do not sell to patients.
- CAS No.: 931305-29-2
- Formula: C21H21N3O3S
- Molecular Weight:395.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DU-145 | IC50 |
0.12 μM
Compound: 2
|
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
In Vitro
Bt354 (0.1-100 μM; 24-72 h) exhibits concentration- and time-dependent antiproliferative activity against U87 MG, GBM8401 and T98G glioblastoma cells, with IC50 values of 9.96 μM, 15.18 μM and 3.39 μM, respectively, after 24 h of incubation[1].
Bt354 (0.01-5 μM; 48 h) induces apoptosis in U87 MG glioblastoma cells in a concentration-dependent manner, and a significant increase in the proportion of apoptotic cells is observed at concentrations of 0.1 μM and above after 48 h of incubation[1].
Bt354 (0.1-5 μM; 24 h) induces apoptosis in U87 MG glioblastoma cells by upregulating the expression of cleaved caspase-3 and cleaved PARP, and reducing the activity of pro-caspase-3; a significant effect is observed at concentrations of 0.1 μM and above after 24 h of incubation[1].
Bt354 (0.1-5 μM; 24 h) inhibits epithelial-mesenchymal transition in U87 MG glioblastoma cells by upregulating E-cadherin expression and downregulating the expressions of vimentin, matrix metalloproteinase-2 (MMP-2), ZEB1 and FOXM1; after 24 h of incubation, significant effects are observed at concentrations of 0.1 μM and above (the effective concentrations for E-cadherin and ZEB1 are 1 μM and above)[1].
Bt354 (0.01-5 μM; 6-18 h) inhibits the migration of U87 MG glioblastoma cells in a concentration- and time-dependent manner. A significant migration-inhibiting effect is observed at concentrations of 0.01 μM and above, and the inhibitory effect reaches the maximum level after 18 h of incubation[1].
Bt354 (0.1-5 μM; 24 h) alters the polymerization state of F-actin in U87 MG glioblastoma cells, converting filamentous F-actin into a globular form near the nucleus; it inhibits cell migration after 24 h of incubation at concentrations of 0.1 μM and above[1].
Bt354 (0.1-5 μM; 24 h) regulates epithelial-mesenchymal transition in U87 MG glioblastoma cells by upregulating E-cadherin expression and downregulating vimentin expression, and this effect occurs at concentrations of 0.1 μM or higher after 24 h of incubation[1].
Bt354 (0.1-5 μM; 24 h) reduces the production of MMP-2 in U87 MG glioblastoma cells in a concentration-dependent manner in vitro, and a significant reduction is observed at concentrations of 0.1 μM and above after 24 h of incubation[1].
Bt354 (24 h) potently inhibits STAT3-dependent luciferase activity in DU145, MDA-MB-435 and MDA-MB-231 cells, with IC50 values of 4.6 μM, 6.5 μM and 7.2 μM, respectively[3].
Bt354 (24-72 h) inhibits the proliferation of DU145, MDA-MB-435 and MDA-MB-231 cells in a time- and dose-dependent manner, with its IC50 values ranging from 0.07 μM to 35 μM depending on the cell line and incubation time[3].
Bt354 specifically inhibits the phosphorylation of STAT3 at the Tyr705 site (without affecting phosphorylation at the Ser727 site or the upstream JAK2/Src signaling pathway), and downregulates the expression of STAT3-dependent pro-proliferative and anti-apoptotic proteins in MDA-MB-435 and MDA-MB-231 cells[3].
Bt354 (0.1-5 μM; 12 h) inhibits the nuclear translocation of STAT3 in MDA-MB-435 and MDA-MB-231 cells in a dose-dependent manner, which is evidenced by the reduced nuclear STAT3 levels after treatment with 1 μM or 5 μM Bt354 for 12 h[3].
Bt354 (0.5 μM; 24 h) induces G2/M cell cycle arrest in MDA-MB-435 and MDA-MB-231 cells[3].
Bt354 (48 h) induces late-stage apoptosis in MDA-MB-435 and MDA-MB-231 cells in a dose-dependent manner, increasing the proportion of late-stage apoptotic cells to 26.0% and 29.5%, respectively[3].
Bt354 (1 μM) inhibits the migration of MDA-MB-435 and MDA-MB-231 cells in a dose-dependent manner, with a significant inhibitory effect observed at the concentration of 1 μM in MDA-MB-435 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:U87 MG glioblastoma cells
-
Concentration:0.01, 0.1, 1 and 5 μM
-
Incubation Time:24 h; 48 h
-
Result:Induced a significant, concentration-dependent increase in the proportion of apoptotic U87 MG cells at concentrations of 0.1 μM to 5 μM after 48 h treatment.
Showed no discernible apoptotic effect after 24 h of treatment at equivalent concentrations.
-
Cell Line:U87 MG glioblastoma cells
-
Concentration:0.1, 1 and 5 μM
-
Incubation Time:24 h
-
Result:Increased cleaved caspase-3 and cleaved PARP expression levels substantially at 1 μM.
Decreased pro-caspase-3 activity significantly in U87 MG cells treated with 0.1 μM and above.\nIncreased E-cadherin expression in a concentration-dependent manner, with significant increase observed at 1 μM and above.
Decreased vimentin, MMP-2, and FOXM1 expression in a concentration-dependent manner, with significant decreases observed at 0.1 μM and above.
Decreased ZEB1 expression in a concentration-dependent manner, with significant decrease observed at 1 μM and above.
Caused no significant changes in SLUG expression.
-
Cell Line:U87 MG glioblastoma cells
-
Concentration:0.01, 0.1, 1 and 5 μM
-
Incubation Time:6 h; 12 h; 18 h
-
Result:Significantly inhibited U87 MG cell migration in a concentration- and time-dependent manner, with significant inhibition observed at 0.01 μM and above.
Increased inhibition over time, with the maximal effect observed at 18 h.
-
Cell Line:U87 MG glioblastoma cells
-
Concentration:0.1, 1 and 5 μM
-
Incubation Time:24 h
-
Result:Altered F-actin polymerization in U87 MG glioblastoma cells, converting filamentous F-actin to a globular form near the nucleus.
Inhibited cell metastasis in treated cells.\nIncreased E-cadherin expression significantly as Bt354 concentration increased.
Decreased vimentin expression significantly with increasing Bt354 concentration.
-
Cell Line:U87 MG glioblastoma cells
-
Concentration:0.1, 1 and 5 μM
-
Incubation Time:24 h
-
Result:Reduced MMP-2 concentration in U87 MG cell supernatant in a concentration-dependent manner.
Showed significant effects at 0.1 μM and above.
-
Cell Line:MDA-MB-435 human triple negative breast cancer cells, MDA-MB-231 human triple negative breast cancer cells
-
Concentration:0.1, 1 and 5 μM
-
Incubation Time:12 h
-
Result:Reduced nuclear STAT3 levels substantially in a dose-dependent manner, with STAT3 remaining primarily in the cytoplasm after treatment with 1 μM or 5 μM Bt354 for 12 h.
-
Cell Line:MDA-MB-435 human triple negative breast cancer cells, MDA-MB-231 human triple negative breast cancer cells
-
Concentration:0.5 μM
-
Incubation Time:24 h
-
Result:Caused G2/M phase accumulation, with G2/M percentages increasing to 28.68% (MDA-MB-435) and 27.50% (MDA-MB-231).
In Vivo
Bt354 (10-40 mg/kg; p.o.; once every 3 days; 21 days) elicits dose-dependent antitumor activity in MDA-MB-231 xenograft mice[3].
Bt354 (10-40 mg/kg; p.o.; once every 3 days; 21 days) elicits dose-dependent antitumor activity in MDA-MB-435 xenograft mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (adult male, 250-285 g, chronic constriction injury of right sciatic nerve, intrathecal catheter implantation prior to CCI induction)[2]
-
Dosage:0.1-20 μg (acute testing); 0.25-1 μg/h (preventive testing)
-
Administration:i.t.; single injection (acute testing); continuous infusion, 7-14 days (preventive testing)
-
Result:Produced dose-dependent analgesic effect on CCI-induced thermal hyperalgesia with pharmacodynamic activity lasting up to 24 hours.
Calculated ED50 of 1.176 μg.
Resulted in significantly higher paw withdrawal threshold values than CCI + vehicle controls from day 3 to day 14 post-surgery.
Elevated paw withdrawal latency values relative to CCI + vehicle controls from day 1 to day 14 post-surgery, with dose-dependent improvement observed.
Significantly attenuated CCI-induced upregulation of STAT3 and phosphorylated STAT3 in the ipsilateral spinal cord dorsal horn, including reduced nuclear translocation of neuronal pSTAT3.
Mitigated CCI-induced activation and pro-inflammatory polarization of microglia and astrocytes.
Suppressed neuronal NLRP3 inflammasome expression.
Reduced neuronal LDHA and pTBK1 expression.
Attenuated microglial pCREB and pP38 expression.
Decreased pro-inflammatory cytokine production in neurons and microglia.
Inhibited CCI-induced angiogenesis.
-
Animal Model:BalB/c-nu/nu (female, 8-10 week old)[3]
-
Dosage:10 mg/kg; 20 mg/kg; 40 mg/kg
-
Administration:p.o.; once every 3 days; 21 days
-
Result:Reduced mean tumor volume to 1303.2 mm3 (10 mg/kg), 976.0 mm3 (20 mg/kg), and 811.0 mm3 (40 mg/kg), compared to 2604.3 mm3 in controls.
Achieved tumor growth inhibition (T/C) values of 50%, 37.4%, and 31.3% for the 10, 20, and 40 mg/kg groups, respectively.
Decreased tumor weight by 74.6% in the 40 mg/kg group.
Reduced p-STAT3(Y705) levels in tumor tissue in a dose-dependent manner.
Lowered Ki-67-positive cell counts in all Bt354-treated groups.
Increased tumor cell apoptosis (measured via TUNEL assay) in a dose-dependent manner across all Bt354 groups.\nReduced mean tumor volume to 393.2 mm3 (10 mg/kg), 351.1 mm3 (20 mg/kg), and 321.4 mm3 (40 mg/kg), compared to 1365.8 mm3 in controls.
Achieved tumor growth inhibition (T/C) values of 28.7%, 25.7%, and 23.5% for the 10, 20, and 40 mg/kg groups, respectively.
Decreased tumor weight by 56.2%, 63.8%, and 77.1% in the 10, 20, and 40 mg/kg groups, respectively.
Reduced p-STAT3(Y705) levels in tumor tissue in a dose-dependent manner.
Lowered Ki-67-positive cell counts in all Bt354-treated groups.
Increased tumor cell apoptosis (measured via TUNEL assay) in a dose-dependent manner across all Bt354 groups.
Chemical Information
-
CAS No. 931305-29-2
-
Molecular Weight 395.48
-
Formula C21H21N3O3S
-
SMILES
O=C(NCC=1C=NC=CC1)C2=CC=C(C(=C2)NS(=O)(=O)C3=CC=C(C=C3)C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
[1]. Chiang YC, et al. STAT3 phosphorylation inhibitor Bt354 exhibits anti-neoplastic activity in glioblastoma multiforme cells. Environ Toxicol. 2024;39(6):3292-3303. [Content Brief]
[2]. Cheng HJ, et al. Intrathecal STAT3 inhibitor Bt354 ameliorates chronic constriction injury-induced nociceptive sensitization by modulating neuroinflammation. Neurotherapeutics. 2025;22(6):e00763. [Content Brief]
[3]. Chen Y, et al. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer. J Drug Target. 2018;26(10):920-930. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)